Skip to main content

Advertisement

SpringerLink
Log in

Pediatric high-grade glioma: current molecular landscape and therapeutic approaches

  • Topic Review
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

High-grade pediatric central nervous system glial tumors are comprised primarily of anaplastic astrocytomas (AA, WHO grade III) and glioblastomas (GBM, WHO grade IV). High-grade gliomas are most commonly diagnosed in the primary setting in children, but as in adults, they can also arise as a result of transformation of a low-grade malignancy, though with limited frequency in the pediatric population. The molecular genetics of high-grade gliomas in the pediatric population are distinct from their adult counterparts. In contrast to the adult population, high-grade gliomas in children are relatively infrequent, representing less than 20% of cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Armstrong CL, Gyato K et al (2004) A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy. Neuropsychol Rev 14(1):65–86

    Article  PubMed  Google Scholar 

  2. Barani IJ, Cuttino LW et al (2007) Neural stem cell-preserving external-beam radiotherapy of central nervous system malignancies. Int J Radiat Oncol Biol Phys 68(4):978–985

    Article  PubMed  Google Scholar 

  3. Barbagallo GM, Certo F, Heiss K, Albanese V (2014 Dec) 5-ALA fluorescence-assisted surgery in pediatric brain tumors: report of three cases and review of the literature. Br J Neurosurg 28(6):750–754

    Article  PubMed  Google Scholar 

  4. Bax DA, Gaspar N et al (2009) EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 15:5753–5761

    Article  CAS  PubMed  Google Scholar 

  5. Bredel M, Pollack IF et al (1999) Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 5(7):1786–1792

    CAS  PubMed  Google Scholar 

  6. Butte PV, Mamelak A, Parrish-Novak J, Drazin D, Shweikeh F, Gangalum PR, Chesnokova A, Ljubimova JY, Black K (2014) Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors. Neurosurg Focus 36(2):E1

    Article  PubMed  Google Scholar 

  7. Castel D, Philippe C, Calmon R et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130(6):815–827

  8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516

  9. Cheng Y, Ng HK, Zhang SF et al (1999) Genetic alterations in pediatric high-grade astrocytomas. Hum. Pathology 30:1284–1290

    CAS  Google Scholar 

  10. Cohen KJ, Pollack IF et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro-oncol 13:317–323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatric Blood Cancer 48:403–407

    Article  PubMed  Google Scholar 

  12. Duffner PK (2007) Diagnosis of brain tumors in children. Expert Rev Neurother 7(7):875–885

    Article  PubMed  Google Scholar 

  13. Estlin EJ, Lashford L et al (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children’s Cancer Study Group. Br J Cancer 78(5):652–661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Faury D, Nantel A et al (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Onocl 25(10):1196–1208

    Article  CAS  Google Scholar 

  15. Ferris SP, Goode B, Joseph NM, Kline CN, Samuel D, Gupta N, Bollen A, Perry A, Mueller S, Solomon DA (2016 Jul) IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age. Acta Neuropathol 132(1):153–155

    Article  PubMed  PubMed Central  Google Scholar 

  16. Finlay JL, Boyett JM et al (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 13(1):112–123

    Article  CAS  PubMed  Google Scholar 

  17. Fontebasso AM, Schwartentruber J et al (2013) Mutations in SETD2 and genes affecting H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 125(5):659–669

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fulton DS, Urtasun RC et al (1992) Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study. J Neurooncol 14(1):63–72

    Article  CAS  PubMed  Google Scholar 

  19. Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR (2005) Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatric Neurosurg 41:292–299

    Article  CAS  Google Scholar 

  20. Grovas AC, Boyett JM et al (1999) Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children’s Cancer Group. Med Pediatr Oncol 33(2):83–87

    Article  CAS  PubMed  Google Scholar 

  21. Gutierrez AN, Westerly DC et al (2007) Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys 69(2):589–597

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hamilton SR, Liu B et al (1995) The molecular basis of Turcot’s syndrome. N Engl J Med 332(13):839–847

    Article  CAS  PubMed  Google Scholar 

  23. Harrow S, Papanastassiou et al (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11:1648–1658

    Article  CAS  PubMed  Google Scholar 

  24. Hegde MR, Chong B et al (2005) A homozygous mutation in MSH6 causes Turcot syndrome. Clin Cancer Res 11(13):4689–4693

    Article  CAS  PubMed  Google Scholar 

  25. Heideman RL, Kuttesch J Jr et al (1997) Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer 80(3):497–504

    Article  CAS  PubMed  Google Scholar 

  26. Hyder DJ, Sung L et al (2007) Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol 83:1–8

    Article  PubMed  Google Scholar 

  27. Jakacki RI, Cohen KJ et al (2016) Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study. Neuro-Oncol 0:1–9.

    Google Scholar 

  28. Jiao Y, Killela PJ et al (2012) Frequent ATRX, CTC, FUBP1 and IDH1 mutations refine the classification of malignant glioma. Oncotarget 3(7):709–722

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kieran MW, Hargrave DR. (2015). Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST). J Clin Oncol 33:10004

    Google Scholar 

  30. Killela PJ, Reitman ZJ et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. PNAS 110(15):6021–6026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kline CN, Joseph NM et al (2016) Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. doi:10.1093/neuonc/now254

  32. Kline C, Durisetti S, Banerjee A, Nicolaides T, Raber S, Gupta N, Haas Kogan D, Braunstein S, Mueller S (2016) Reirradiation with and without PD-1 inhibition for diffuse intrinsic pontine glioma: a single-institution experience. Society for Neuro-Oncology Annual Meeting 2016

  33. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129(5):669–678

  34. Lashford LS, Thiesse P et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20(24):4684–4691

    Article  CAS  PubMed  Google Scholar 

  35. Li FP, Fraumeni JF Jr et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358–5362

    CAS  PubMed  Google Scholar 

  36. Liang M-L, Ma J et al (2008) Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol 87:247–253

    Article  PubMed  Google Scholar 

  37. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. doi:10.1007/s00401-016-1545-1

  38. Marachelian A, Butturini A et al (2008) Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transpl 41(2):167–172

    Article  CAS  Google Scholar 

  39. Massimino M, Gandola L et al (2005) Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro-Oncol 7(1):41–48

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Mehta V, Chapman A et al (2002) Latency between symptom onset and diagnosis of pediatric brain tumors: an Eastern Canadian geographic study. Neurosurgery 51(2):365–372 (discussion 372–373)

    Article  PubMed  Google Scholar 

  41. Merchant TE, Hua CH et al (2008) Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatric Blood Cancer 51(1):110–117

    Article  PubMed  Google Scholar 

  42. Merchant TE, Conklin HM et al (2009) Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prostpective evaluation of cognitive, endocrine, and hearing defects. J Clin Oncol 27(22):3691–3697

    Article  PubMed  PubMed Central  Google Scholar 

  43. Mueller S, Phillips J et al (2012) PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro-Oncol 14(9):1146–1152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Mueller S, Fullerton HJ et al (2013) Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. IJROBP 86(4):649–655

    Google Scholar 

  45. Nakamura M, Shimada K et al (2007) Molecular pathogenesis of pediatric astrocytic tumors. Neuro-oncol 9(2):113–123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Nicholson HS, Kretschmar CS et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer 110(7):1542–1550

    Article  CAS  PubMed  Google Scholar 

  47. Nicoliades TP, Li H et al (2011) Targeted therapy for BRAF V600E malignant astrocytoma. Clin Cancer Res 21(6):7595–7604

    Article  Google Scholar 

  48. Packer RJ (1999) Primary central nervous system tumors in children. Curr Treat Options Neurol 1(5):395–408

    Article  CAS  PubMed  Google Scholar 

  49. Packer RJ, Boyett JM et al (1993) Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. Cancer 72(4):1414–1421

    Article  CAS  PubMed  Google Scholar 

  50. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265–277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Paugh BS, Qu C et al (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. Journal of clinical Oncology 28(18):3061–3068

    Article  PubMed  PubMed Central  Google Scholar 

  52. Pettorini BL, Park YS et al (2008) Radiation-induced brain tumours after central nervous system irradiation in child-hood: a review. Childs Nerv Syst 24(7):793–805

    Article  PubMed  Google Scholar 

  53. Pollack IF (1994) Brain tumors in children. N Engl J Med 331(22):1500–1507

    Article  CAS  PubMed  Google Scholar 

  54. Pollack IF, Finkelstein SD et al (2001) Age and TP53 mutation frequency in childhood malignant gliomas: results in a multiinstitutional cohort. Cancer Res 61(20):7404–7407

    CAS  PubMed  Google Scholar 

  55. Pollack IF, Finkelstein SD et al (2002) Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346(6):420–427

    Article  CAS  PubMed  Google Scholar 

  56. Pollack IF, Hamilton RL et al (2006) Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children’s Cancer Group 945 cohort. J Neurosurg 105(5 Suppl):418–424

    PubMed  Google Scholar 

  57. Pollack IF, Hamilton RL et al (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol 24(21):3431–3437

    Article  CAS  PubMed  Google Scholar 

  58. Pollack IF, Hamilton RL et al (2010) Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children’s Oncology Group. J Neurooncol 99:155–163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Pollack IF, Hamilton RL et al (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Child’s Nervous System 27(1):87–94

    Article  PubMed  Google Scholar 

  60. Pollack IF, Jakacki RI et al (2014) Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 32(19):2050–2058

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Raffel C, Frederick L, O’Fallon JR et al (1999) Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin. Cancer Res 5:4085–4090

    CAS  Google Scholar 

  62. Robinson GW, Orr BA, Gajjar A (2014) Complete clinical regression of a BRAF B600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14:258

    Article  PubMed  PubMed Central  Google Scholar 

  63. Schiffman JD, Hodgson JG et al (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70:512–519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Schwartzentruber J, Korshunov A et al (2012) Driver mutations in histone H3.3 and chromatin remodeling genes in paediatric glioblastoma. Nature 482(7384):226–231

    Article  CAS  PubMed  Google Scholar 

  65. Setty P, Hammes J et al (2010) A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. The Journal of Molecular Diagnostics 12(6):750–756

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Sposto R, Ertel IJ et al (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Children’s Cancer Study Group. J Neurooncol 7(2):165–177

    Article  CAS  PubMed  Google Scholar 

  67. Sturm D, Witt H et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437

    Article  CAS  PubMed  Google Scholar 

  68. Stupp R, Mason WP et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):997–1003

    Article  PubMed  Google Scholar 

  69. Sure U, Ruedi D, Tachibana O et al (1997) Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. Journal Neuropathology. Exp Neurol 56:782–789

    CAS  Google Scholar 

  70. Tamber MS, Rutka JT (2003) Pediatric supratentorial highgrade gliomas. Neurosurg Focus 14(2):e1

    Article  PubMed  Google Scholar 

  71. Thorarinsdottir HK, Santi M, McCarter R, Rushing EJ, Cornelison R, Jales A, MacDonald TJ (2008) Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res 14(11):3386–3394

  72. Turcot J, Despres JP et al (1959) Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 2:465–468

    Article  CAS  PubMed  Google Scholar 

  73. Varley JM, McGown G et al (1997) Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57(15):3245–3252

    CAS  PubMed  Google Scholar 

  74. Warren KE (2013) Novel therapeutic delivery approaches in development for pediatric gliomas. CNS Oncol 2(5):427–435. doi:10.2217/cns.13.37

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Wisoff JH, Boyett JM et al (1998) Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 89(1):52–59

    Article  CAS  PubMed  Google Scholar 

  76. Wolff JE, Gnekow AK et al (2002) Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 94(1):264–271

    Article  CAS  PubMed  Google Scholar 

  77. Wolff JE, Driever PH et al (2010) Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 116(3):705–712

    Article  PubMed  Google Scholar 

  78. Wu G, Broniscer A et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Wu G, Diaz AK et al (2014) The genomic landscape of diffuse intrinsic pontine gliomas and pediatric non-brainstem high-grade gliomas. Nat. Genetics 46(5):444–450

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Yang T, Temkin N et al (2013) Gross total resection correlates with long-term survival in pediatric patients with glioblastoma. World. Neurosurgery 79(3–4):537–544

    Google Scholar 

  81. Zaghloul MS, Eldebawy E et al (2014) Hypofractioned conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiotherapy. Int Soc Cell 111(1):35–40

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

    Steve Braunstein & David Raleigh

  2. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA

    Ranjit Bindra

  3. Departments of Neurology, Neurosurgery and Pediatrics, University of California San Francisco, San Francisco, CA, USA

    Sabine Mueller

  4. Department of Radiation Oncology, DFCI/BWH, Boston, MA, USA

    Daphne Haas-Kogan

Authors
  1. Steve Braunstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Raleigh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ranjit Bindra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabine Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daphne Haas-Kogan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steve Braunstein.

Ethics declarations

Conflict of interest

Steve Braunstein declares he has no conflict of interest. David Raleigh declares he has no conflict of interest. Ranjit Bindra declares he has no conflict of interest. Sabine Mueller declares she has no conflict of interest. Daphne Haas-Kogan declares she has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Steve Braunstein and David Raleigh have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Braunstein, S., Raleigh, D., Bindra, R. et al. Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol 134, 541–549 (2017). https://doi.org/10.1007/s11060-017-2393-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2393-0

Keywords

Search

Navigation